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794Objectives: MicroRNAs (miRNAs) are widely known for their function as regulators of gene expression
via translational repression. Polymorphisms in miRNAs have been shown to affect the regulatory capacity of
miRNAs by influencing miRNA processing and/or miRNA-mRNA interactions. The purpose of this study
was to investigate the association between 7 single nucleotide polymorphisms (SNPs) commonly found in pre-
cursor miRNA (pre-miRNA) and primary miRNA (pri-miRNA) sequences and the recurrence of disease in pa-
tients who underwent a complete resection of non–small cell lung cancer (NSCLC).
Methods: Five SNPs found in pre-miRNAs (rs11614913/miR-196a2, rs2910164/miR-146a, rs6505162/miR-
423, rs2289030/miR-492, and rs895819/miR-27a) and 2 SNPs found in pri-miRNAs (rs7372209/miR-26a-1
and rs213210/miR-219-1) were genotyped in 388 patients with NSCLC.
Results: Among 388 patients, variants of the rs2910164 SNP were significantly associated with recurrence-free
survival (RFS) (P ¼ .016, log–rank test). When the results were subdivided by the tumor stage, variants of the
rs2910164 and rs11614913 SNPs positively correlated with a better RFS (adjusted hazard ratio [HR], 0.48; 95%
confidence interval [CI], 0.28-0.80; adjusted HR, 0.60; 95% CI, 0.38-0.94, respectively) in patients with stage II
and stage III disease. Moreover, RFS significantly improved in patients with higher numbers of variant alleles in
the rs2910164 and rs11614913 SNPs.
Conclusions: Our findings suggest that polymorphisms in the rs2910164 of miR-146a and the rs11614913 of
miR-196a2 are associated with prognosis in patients with completely resected NSCLC. (J Thorac Cardiovasc
Surg 2012;144:794-807)MicroRNAs (miRNA) are endogenous, small, noncoding
RNAs that play important roles in the posttranscriptional
regulation of messenger RNA (mRNA) expression.1,2
Mature miRNAs are generated from precursor miRNAs
(pre-miRNAs), which are the processed products of the
longer primary miRNA (pri-miRNA) transcripts.3,4
MicroRNAs regulate gene expression by translational
inhibition or mRNA cleavage, and these mechanisms are
dependent on complete or nearly complete sequence
complementarity.2 Many studies have reported that the dys-
function of miRNAs that target oncogenic or tumor sup-
pressor activity can influence cancer development.5-8 The
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The Journal of Thoracic and Cardiovascular Surgsuggested by various reports that have characterized the
cellular functions of miRNAs as well as by miRNA
expression profiling in various cancers. For example, the
first miRNA to be associated with lung cancer was let-7,
and decreased let-7 expression was shown to lead to an
increase in the expression level of its target RAS.9,10
Recently, several miRNA polymorphisms have been re-
ported to modify the regulatory capacity of their respective
miRNA by affecting miRNA processing and/or miRNA-
mRNA interactions.11,12 With respect to cancer, miRNA
single nucleotide polymorphisms (SNPs) can be used as
genetic markers to predict cancer susceptibility and
prognosis. For example, the pri-miRNA SNP rs213210
found in miR-219-1 correlates with an increased risk for
esophageal cancer,13 and the variants of the rs7372209
SNP found in miR-26a-1 have been associated with the
prognosis for colon cancer.14 The SNPs rs2289030 found
in pre-miR-492 and the SNP rs6505162 found in pre-
miR-423 have been correlated with an increased risk for
bladder cancer in white subjects.15 The pre-miRNA SNP
rs895819 found in pre-miR-27a has also been shown to be
related to gastric cancer susceptibility and a reduced risk
for familial breast cancer.16,17 Two functional
polymorphisms, rs11614913 in miR-196a2 and rs2910164
in miR-146a, also appear to contribute to the clinicalery c October 2012
Abbreviations and Acronyms
CI ¼ confidence interval
HR ¼ hazard ratio
miRNA ¼ microRNA
mRNA ¼ messenger RNA
NSCLC ¼ non–small cell lung cancer
pre-miRNA ¼ precursor microRNA
pri-miRNA ¼ primary microRNA
RFS ¼ recurrence-free survival
SNP ¼ single nucleotide polymorphism
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Soutcome of various cancers, suggesting that mature miR-
NAs have regulatory roles as well.17,18 To evaluate the
association between miRNA polymorphisms and patient
prognosis of non–small cell lung cancer (NSCLC), we
evaluated whether 7 SNPs in various pre-miRNAs and
pri-miRNAs could predict the clinical outcomes of patients
who underwent complete resection for NSCLC.
METHODS
Study Population
This study included 388 patients who had undergone surgical resections
for NSCLC at the National Cancer Center in Korea from 2001 to 2008, and
follow-up information was available for every patient. The clinicopatho-
logic characteristics of the patients with lung cancer are shown in
Table 1. We retrospectively reviewed the medical and pathology records
for each patient. Chest computed tomography, positron emission tomogra-
phy, bronchoscopy, and pulmonary function tests were performed preoper-
atively. Chest computed tomography scans were obtained postoperatively
at 3-month intervals, and positron emission tomography–computed tomog-
raphy scans were obtained annually to detect recurrence of the tumor.
The patients were histologically diagnosed with pathologic stage I, II, or
IIIA adenocarcinoma or squamous cell carcinoma after the pulmonary
resection and complete lymph node dissection. Criteria for patient exclu-
sion included patients who underwent a limited resection such as a wedge
resection or segmentectomy and patients who underwent neoadjuvant
chemotherapy treatment. The patients voluntarily donated blood for ge-
netic tests after signing an informed consent form, which was previously
approved by the institutional review board.
The recurrence-free survival (RFS) rate was calculated from the date of
surgery to the date of recurrence or to the date of the last follow-up. Local
recurrences were defined as lesions occurring within the resection margins
such as bronchial stumps or staple lines. Regional recurrences were defined
as lesions that occurred within the hilar or mediastinal lymph nodes, pleural
cavity, or ipsilateral lung. Distant recurrences were defined as lesions
occurring within the contralateral lung, brain, liver, adrenal glands, bone,
or other locations.
Selection and Genotyping of the miRNA
Polymorphisms
The candidate miRNA polymorphisms were selected on the basis of
a previously identified association with cancer risk or prognosis by con-
ducting a literature review.10-19 The minor allele frequency was also
considered during the selection of the target SNPs. Data from the
International HapMap Project was used to select SNPs that have a minor
allele frequency greater than 20% in Asians for our analysis. Five
SNPs in pre-miRNAs (rs11614913/miR-196a2, rs2910164/miR-146a,The Journal of Thoracic and Cars6505162/miR-423, rs2289030/miR-492, and rs895819/miR-27a) and
2 SNPs in pri-miRNAs (rs7372209/miR-26a-1 and rs213210/miR-219-1)
fit the aforementioned criteria and were selected for genotyping analysis.
Genomic DNAwas extracted from the peripheral blood using the QIAamp
DNA Blood Mini Kit (Qiagen, Valencia, Calif) according to the manufac-
turer’s instructions. Genotyping was conducted with TaqMan probes using
a 50-nuclease assay (Applied Biosystems, Foster City, Calif). To confirm
the reproducibility of our method, 50 samples were genotyped in duplicate,
and all samples showed concordant results.
Statistical Analysis
Patients who currently smoked or who smoked more than 100 cigarettes
during their lifetime were defined as ever-smokers. The Hardy-Weinberg
equilibrium of each allele was calculated to ensure that the genotyping re-
sults were reliable. The correlation between miRNA polymorphisms and
clinicopathologic characteristics was analyzed using the c2 test. We ana-
lyzed the association between the miRNA polymorphisms and NSCLC
prognosis with respect to the cancer stage. The RFS rates were assessed us-
ing the Kaplan-Meier product limit method, and the trend among the
miRNA polymorphisms was estimated with the log–rank test. The hazard
ratios (HRs) and the associated 95% confidence intervals (CIs) were de-
rived from a Cox proportional-hazards regression model. The statistically
significant (P<.05) covariates from the log–rank test (age, gender, smoking
status, histologic tumor type, stage, and postoperative complications) were
further analyzed after adjustment in a multivariable Cox proportional-
hazards regression model using RFS as the dependent variable. We also an-
alyzed statistically significant polymorphisms that occurred in combination
with other polymorphisms, and individuals were represented by categories
for the number of variant alleles present in the polymorphisms studied. All
of the reported P values were 2-sided. Stata/SE version 11 (StataCorp LP,
College Station, Tex) was used for all statistical analyses.RESULTS
Patient Characteristics
Tumor recurrence was assessed in 388 patients who had
undergone surgical resection of the lung and had clinical
information available for review. The ever-smokers and pa-
tients with early-stage (stage IA/IB) cancer and adenocarci-
noma were dominant in this group. We observed recurrence
in 71 patients over a median follow-up period of 36.8
months. By univariate analysis, gender, smoking status, his-
tology, and pathologic tumor stage were all significantly
associated with the survival outcome (log–rank P< .05)
(Table 1). These factors and notable clinical factors such
as age and postoperative complication were adjusted as
covariates in a multivariate Cox regression analysis.
Specifically, the patients with advanced-stage disease had
a significantly poorer clinical outcome (HR, 3.56; 95%
CI, 2.21-5.74) when compared with the patients with stage
I cancer. Adjuvant chemotherapy was not associated with
RFS. The patients with lung squamous cell carcinoma had
a higher risk of death than did those with adenocarcinoma
(HR, 2.00; 95% CI, 1.25-3.20).The Effects of miRNA Polymorphisms on
Clinicopathologic Characteristics
We conducted stratified and interaction analyses of
7 miRNA polymorphisms with the major clinicopathologicrdiovascular Surgery c Volume 144, Number 4 795
TABLE 1. Demographic characteristics of the patients with lung cancer
Characteristic Cases
Recurrence
No. of events* HR (95% CI) Log–rank test, P value
Total, no. 388 71
Age, y .633
Mean  SD 62.7  9.2 <63.5z 36 (19) Reference
Median (range) 63.5 (34-85) 63.5z 35 (18) 1.12 (0.70-1.79)
Gender, no. .017
Male, n (%) 259 (67) 57 (22) Reference
Female, n (%) 129 (33) 14 (11) 0.49 (0.27-0.88)
Smoking status, no. .047
Never, n (%) 137 (35) 17 (12) Reference
Ever, n (%) 251 (65) 54 (22) 1.74 (1.01-3.00)
Histology, no. .004
Adenocarcinoma, n (%) 242 (62) 32 (13) Reference
Squamous cell carcinoma, n (%) 146 (38) 39 (27) 2.00 (1.25-3.20)
Pathologic atage (AJCC 7th edition) <.001
IA, n (%) 135 (35) 7 (5) Reference
IB, n (%) 116 (30) 21 (18) 4.31 (1.83-10.16)
IIA, n (%) 43 (11) 11 (26) 5.79 (2.24-14.94)
IIB, n (%) 24 (6) 6 (25) 6.24 (2.09-18.59)
IIIA, n (%) 70 (18) 26 (37) 11.60 (5.02-26.80)
Postoperative complication .133
No, n (%) 297 (77) 52 (18) Reference
Yes, n (%) 91 (23) 19 (21) 1.50 (0.88-2.55)
Adjuvant chemotherapy .495
No, n (%) 303 (78) 54 (18) Reference
Yes, n (%) 85 (22) 17 (20) 1.21 (0.70-2.10)
Follow-up time, moy
Median (95% CI) 36.8 (39.5-44.8)
Range (0.1-108.9)
HR, Hazard ratio; CI, confidence interval; SD, standard deviation; AJCC, American Joint Committee on Cancer. *Number of recurrences. yThe median follow-up time, 95%
confidence interval, and range were calculated among censored observations only. zDichotomized by the median data point.
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Svariables. Age, gender, and smoking were not associated
with any of the miRNA polymorphisms (Appendix Table
1). In 108 patients with nodal metastasis, there was no dif-
ference between micrometastasis and overt nodal metasta-
sis and any of the miRNA polymorphisms. The CC
genotype of the rs7372209 SNP was more evident in squa-
mous cell carcinoma (P ¼ .014). The CC genotype of the
rs2910164 SNP was associated with more advanced patho-
logic staging (P ¼ .036). In the multivariate analysis
(Appendix Table 2), the CC genotype of the rs2910164
SNP was more frequently found in patients with stage II
and IIIA disease than in those with stage I disease
(P<.01; HR, 0.48; 95% CI, 0.28-0.80).
The Effects of miRNA Polymorphisms on RFS
The rates for overall survival and RFS were 84.8% and
74.5% in all patients, respectively. The RFS was selected
as the primary end point because additional treatment mo-
dalities could affect the survival of the patients after cancer
recurrence. The association analysis between RFS and
miRNA polymorphisms revealed that variants of the
rs2910164 polymorphism in miR-146a were associated796 The Journal of Thoracic and Cardiovascular Surgwith an improved RFS in all of the patients (adjusted HR,
0.65; 95% CI, 0.45-0.93; P ¼ .019). Inasmuch as the path-
ologic stage of the cancer is an important factor that affects
the clinical outcome, the effects of the polymorphisms on
the RFS in stage I and higher-stage patients (stage II/III)
were further evaluated with stratified analyses. As shown
in Table 2, two polymorphisms were significantly associ-
ated with the survival of patients with stage II and III dis-
ease. Specifically, the rs2910164 allele was associated
with an increased RFS in patients with a relatively ad-
vanced cancer stage (adjusted HR, 0.48; 95% CI, 0.28-
0.80; P ¼ .005 in an additive model). The Kaplan-Meier
analysis revealed that the CC genotype of the rs2910164
SNP was associated with poor survival in patients with
stage II and III disease (log–rank P¼ .0047; Figure 1). Ad-
ditionally, the rs11614913 allele in miR-196a2 reduced the
HR for the RFS in patients with advanced-stage cancer (ad-
justed HR, 0.60; 95% CI, 0.38-0.94; P ¼ .026 in an addi-
tive model). The cumulative effects of these 2 SNPs were
evaluated in the patients, and the rs2910164 and
rs11614913 variant alleles exhibited a trend toward associ-
ating with a prolonged RFS in patients with all stages ofery c October 2012
TABLE 2. The association between the 7 miRNA polymorphisms and the recurrence-free survival according to the pathologic stages of lung cancer
Genotypes
Total (n ¼ 388) Stage I (A/B) Stage II (A/B) and stage IIIA
No. of
pts.
No.
relapsed
Log–rank
trend test,
P valuey
Adjusted
HR (95% CI)*
No.
of pts.
No.
relapsed
Log– rank
trend test,
P valuey
Adjusted
HR (95% CI)*
No.
of pts.
No.
relapsed
Log– rank
trend test,
P valuey
Adjusted
HR (95% CI)*
mir219-1 rs213210
AA 105 17 .56 Ref. 75 7 .515 Ref. 30 10 .91 Ref.
AG 182 35 1.16 (0.65-2.08) 113 12 1.14 (0.44-2.95) 69 23 1.13 (0.53-2.41)
GG 100 19 1.18 (0.60-2.31) 62 9 1.20 (0.43-3.38) 38 10 0.91 (0.37-2.24)
AGþGG 282 54 1.17 (0.67-2.03) 175 21 1.16 (0.48-2.81) 107 33 1.06 (0.51-2.18)
Trend for G allele 1.09 (0.78-1.51) 1.10 (0.66-1.83) 0.95 (0.62-1.47)
mir27a rs895819
TT 185 32 .984 Ref. 127 12 .630 Ref. 58 20 .367 Ref.
CT 158 32 1.03 (0.62-1.72) 98 13 1.46 (0.65-3.29) 60 19 0.93 (0.48-1.84)
CC 45 7 0.81 (0.35-1.85) 26 3 1.20 (0.33-4.41) 19 4 0.64 (0.21-1.92)
CTþCC 203 39 0.98 (0.61-1.60) 124 16 1.4 (0.65-3.03) 79 23 0.86 (0.45-1.65)
Trend for C allele 0.94 (0.66-0.35) 1.20 (0.69-2.07) 0.84 (0.52-1.35)
mir492 rs2289030
GG 237 41 .961 Ref. 154 16 .776 Ref. 83 25 .869 Ref.
CG 132 28 1.12 (0.69-1.83) 84 12 1.37 (0.64-2.93) 48 16 1.08 (0.57-2.07)
CC 19 2 0.56 (0.14-2.33) 13 0 NA 6 2 1.09 (0.25-4.69)
CGþCC 151 30 1.04 (0.65-1.69) 97 12 1.17 (0.55-2.48) 54 18 1.08 (0.58-2.02)
Trend for C allele 0.96 (0.65-1.44) 0.95 (0.50-1.78) 1.07 (0.63-1.79)
mir146a rs2910164
CC 177 43 .016 Ref. 104 12 .891 Ref. 73 31 .006 Ref.
CG 159 20 0.52 (0.31-0.89) 111 11 0.75 (0.32-1.76) 48 9 0.39 (0.19-0.83)
GG 51 8 0.53 (0.24-1.13) 35 5 1.11 (0.38-3.22) 16 3 0.30 (0.09-1.00)
CGþGG 210 28 0.52 (0.32-0.85) 146 16 0.84 (0.39-1.82) 64 12 0.37 (0.19-0.71)
Trend for G allele 0.65 (0.45-0.93) 0.98 (0.57-1.7) 0.48 (0.28-0.80)
mir423 rs6505162
CC 244 44 .887 Ref. 157 16 .691 Ref. 87 28 .866 Ref.
AC 120 24 1.18 (0.71-1.95) 78 11 1.41 (0.65-3.08) 42 13 1.02 (0.52-2.00)
AA 21 3 0.69 (0.21-2.24) 14 1 1.02 (0.13-7.97) 7 2 0.81 (0.19-3.41)
ACþAA 141 27 1.09 (0.67-1.77) 92 12 1.37 (0.64-2.94) 49 15 0.98 (0.51-1.87)
Trend for A allele 1.00 (0.68-1.47) 1.24 (0.65-2.33) 0.96 (0.57-1.61)
mir26a-1 rs7372209
CC 204 36 .606 Ref. 128 13 .639 Ref. 76 23 .715 Ref.
CT 154 28 1.16 (0.70-1.91) 105 13 1.29 (0.59-2.83) 49 15 1.03 (0.53-2.02)
TT 30 7 1.14 (0.50-2.62) 18 2 1.64 (0.36-7.47) 12 5 1.34 (0.50-3.62)
CTþTT 184 35 1.16 (0.72-1.86) 123 15 1.33 (0.62-2.84) 61 20 1.10 (0.59-2.03)
Trend for T allele 1.10 (0.77-1.57) 1.28 (0.70-2.36) 1.12 (0.71-1.76)
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Scancer (adjusted HR, 0.74; 95% CI, 0.59-0.93; P¼ .011).
However, the Kaplan-Meier analysis revealed that the ef-
fect of the 2 SNPs was only significant for patients with
stage II and III cancer (Figure 2). The patients carrying
a greater amount of variant alleles of these 2 SNPs had
a significantly prolonged RFS (adjusted HR, 0.57; 95%
CI, 0.41-0.78; P ¼ .0005; Table 3).Effect of Adjuvant Chemotherapy on Patient
Outcome by miRNA SNPs
Platinum-based adjuvant chemotherapy was prescribed
in 85 patients at approximately 6 weeks after surgery. The
most common treatment modality prescribed was gemci-
tabine (Gemzar; Eli Lilly, Indianapolis, Ind) plus cisplatin
(n ¼ 32, 38%). The rs2910164 allele was associated with
a significantly altered risk of RFS in patients receiving
chemotherapy (Appendix Table 3). In patients who re-
ceived adjuvant chemotherapy, the recurrence of disease
in patients who expressed the variant miRNA allele was
10.6%, whereas the recurrence in the patients carrying
the CC genotype was 31.6% (P ¼ .003). Interestingly,
a similar effect was shown by variant genotypes of
rs11614913. In patients who received adjuvant chemo-
therapy, the recurrence rate in patients harboring the var-
iant genotypes was 12.7%, whereas the survival of the
patients carrying the CC genotype was 42.9% (P¼ .037).
The patients who had lymph nodal metastasis (n¼ 108)
were dichotomized on the basis of whether micrometasta-
ses were discovered after the operation. The Kaplan-
Meier analysis revealed that the CC genotype of the
rs2910164 allele associates with poor survival in patients
with micrometastasis (adjusted HR, 0.117; 95% CI,
0.027-0.495; P ¼ .004 in an additive model). However,
the sample number was too small to confidently draw con-
clusions (Appendix Table 4).DISCUSSION
In this study, polymorphisms in certain miRNAs were
significantly associated with lung cancer prognosis in pa-
tients who underwent complete resections. Genetic vari-
ants in miRNAs have been investigated as genetic
markers to predict cancer susceptibility and prognosis.
miRNA polymorphisms could have effects on cellular
function through the regulation of the primary transcript
levels, pre- miRNA and pri-miRNA processing, and the
interaction between the miRNA and the target
mRNA.12 Polymorphisms of the miRNA binding site
have been suggested to be functional SNPs that affect
the binding affinity of miRNAs to their targets. The func-
tional significance of miRNA polymorphisms and the in-
teraction between miRNA and mRNA make it feasible to
evaluate the potential associations between miRNA poly-
morphisms and cancer prognosis.ry c October 2012
FIGURE 1. Recurrence-free survival (RFS) of patients according to the
rs2910164 genotypes by cancer stage. A, All. B, Stage I. C, Stages II
and III. CI, Confidence interval.
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SIn the current study, we analyzed the genotype frequen-
cies and the clinical information from 388 patients to test
the effects of 7 published miRNA polymorphisms on
lung cancer recurrence. Among the miRNA SNPs ana-
lyzed, variants of the rs2910164 polymorphism in miR-
146a were strongly associated with RFS in patients with
NSCLC. Patients with advanced-stage NSCLC who ex-
pressed the variant allele of the rs2910164 locus correlated
with an increased RFS. Regarding survival, an associationThe Journal of Thoracic and Cabetween the rs2910164 polymorphism and cancer has been
reported in esophageal cancer, hepatocellular carcinoma,
breast cancer, and thyroid cancer.20-23 The rs2910164
polymorphism represents a functional polymorphism in
miR-146a that is located in the 30 miRNA passenger strand
and alters the expression of the mature sequence. The var-
iant G allele of the rs2910164 locus was associated with in-
creased expression of mature miR-146a, and increased
expression of miR-146a was found to suppress breast can-
cer metastasis.23 Recently, a potential therapeutic applica-
tion of miR-146a was suggested for treating cancer. The
inhibitory function of miR-146a on cancer invasion has
also been reported in pancreatic cancer cells that overex-
press epidermal growth factor receptor and its target, the
nuclear factor-kB regulatory kinase interleukin-1 recep-
tor-associated kinase 1.24 Our results revealed a significant
association between the rs2910164 polymorphism and lung
cancer prognosis in patients with advanced-stage disease,
suggesting that the variant allele and the resultant increase
in mature miR-146a levels might be involved in the inhibi-
tion of recurrence.
Variants of the rs11614913 polymorphism found in miR-
196a2 also exhibited a positive association with the RFS in
patients with stage II/III disease. The association of
rs11614913 with prognosis has been reported for various
types of cancer. For example, patients who harbor the vari-
ant TT genotype have significantly reduced overall survival
among patients with pharyngeal tumors.25 However, our
data show that the TT genotype is associated with a poor
RFS in early-stage patients only.
Given that the prognosis of cancer patients likely in-
volves multistep, multigenic pathways, it is unlikely that
any single miRNA polymorphism would have a dramatic
effect on the survival outcome. Therefore, it is important
to conduct pathway-based analyses that assess the com-
bined effects of polymorphisms that might interact in the
same pathway. To this end, we used a multigenic approach
to evaluate the associations of miRNA SNPs with the sur-
vival and outcome of patients with surgically resected
NSCLC. Our data reveal that 2 SNPs and their combined
genotypes were associated with the survival outcome of pa-
tients with NSCLC. These findings suggest that SNPs in
miRNAs, and particularly the combined genotypes of sev-
eral SNPs, can be used as prognostic factors for patients
with surgically resected NSCLC.
The most significant finding of this study was that the
combined analysis of multiple SNPs in miRNAs that regu-
late the same or similar pathways had a much higher poten-
tial value in terms of revealing polymorphisms of
prognostic importance. Although 2 SNPs were associated
with the survival outcome in individual SNP analysis, con-
sidering the borderline CI and multiple comparisons, the
impact of any individual miRNA SNP on survival outcomes
is probably minimal. However, when these 2 SNPs wererdiovascular Surgery c Volume 144, Number 4 799
FIGURE 2. Kaplan-Meier curves showing the recurrence-free survival (RFS) probability according to the number of variant alleles from the combination
of the rs2910164 (G allele) and rs11614913 (C allele) polymorphisms by cancer stage. A, Stage I. B, Stages II and III. CI, Confidence interval.
TABLE 3. The additive effects of the combination of rs2910164 (G allele) and rs11614913 (C allele) on the recurrence-free survival according to the
clinical stages of lung cancer patients
Pathologic stage
rs2910164 (G allele)
& rs11614913 (C allele)
combined No. of patients No. relapsed
Recurrence
rate,%
Log–rank trend
test, P value*
Adjusted
P
valueHR (95% CI)y
All 0 variant alleles 49 15 31 .0039 Ref.
1 variant allele 117 27 23 0.82 (0.43-1.55) .5368
2 variant alleles 142 19 13 0.48 (0.24-0.95) .0351
3 variant alleles 60 7 12 0.36 (0.15-0.88) .0258
4 variant alleles 17 3 18 0.63 (0.18-2.22) .4755
Trend 0.74 (0.59-0.93) .0113
Stage I 0 variant alleles 28 4 14 .7667 Ref.
1 variant allele 71 7 10 0.95 (0.27-3.31) .9324
2 variant alleles 97 10 10 0.79 (0.24-2.60) .6976
3 variant alleles 40 4 10 0.68 (0.17-2.79) .5959
4 variant alleles 14 3 21 1.56 (0.34-7.13) .5688
Trend 1.00 (0.70-1.43) .9922
Stages II and IIIA 0 variant alleles 21 11 52 .0003 Ref.
1 variant allele 46 20 43 0.82 (0.39-1.75) .6126
2 variant alleles 45 9 20 0.35 (0.14-0.85) .0208
3 variant alleles 20 3 15 0.22 (0.06-0.79) .0207
4 variant alleles 3 0 0 NA .9875
Trend 0.57 (0.41-0.78) .0005
HR, Hazard ratio; CI, confidence interval; Ref., reference. *Trend for an increasing number of variant alleles. yThe HRs and 95% CIs were derived from a Cox proportional-
hazard regression model controlling for age, gender, smoking status, histologic tumor type, stage, and postoperative complications as covariates.
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number of polymorphisms that confer an increased RFS
when analyzed individually.
Our study was limited to patients who underwent com-
plete resection without prior treatment and focused on the
patient RFS to avoid heterogeneity in the interpretation of
the results. However, further biological and/or functional
evidence is needed to confirm the genetic effects of these
polymorphisms on lung cancer prognosis in these patients.
Despite the importance of the protective effect of these
miRNA polymorphisms on the RFS of NSCLC patients
who underwent complete resections, this study only consid-
ered the Korean population, which may limit the application
of these findings to other ethnicities. Furthermore, the sub-
set analysis with respect to cancer stage was limited by the
sample size, particularly for patients with stages II and III
NSCLC.
In conclusion, the results indicated that there is a signifi-
cant association between miRNA polymorphisms and
NSCLC prognosis. These results suggest that the presence
of variant alleles in miR-146a and miR-196a2 may serve
as prognostic markers for the recurrence of completely re-
sected lung cancer.We are indebted to Geon Kook Lee, MD, PhD, who provided
the samples from the tumor bank of National Cancer Center in
Korea. We also thank Jihye Han and Mee Kyung Jung at the Na-
tional Cancer Center in Korea for data collection and statistical
review.
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APPENDIX TABLE 1. Association between miRNA polymorphisms and clinicopathologic characteristics
Age (n ¼ 388) Gender (n ¼ 388) Smoking (n ¼ 388) Histology (n ¼ 388) P staging (n ¼ 388) Postop. complication (n ¼ 388) Nodal metastasis (n ¼ 108)
<63.5 63.5
c2
P value M F
c2
P value Never Ever
c2
P value Adeno Squamous
c2
P value I II/IIIA
c2
P value No Yes
c2
P value Micrometa
Overt
meta
c2
P value
rs213210
AA 46 59 64 41 45 60 72 33 75 30 85 20 8 15
AG 93 89 121 61 63 119 113 69 113 69 139 43 20 34
GG 54 46 .311 74 26 .137 28 72 .082 56 44 .178 62 38 .230 72 28 .319 12 19 .957
AGþGG 147 135 .180 195 87 .161 91 191 .069 169 113 .149 175 107 .111 211 71 .259 32 53 .993
rs895819
TT 98 87 129 56 62 123 118 67 127 58 135 50 15 31
CT 77 81 97 61 59 99 101 57 98 60 125 33 17 28
CC 19 26 .398 33 12 .160 16 29 .760 23 22 .253 26 19 .259 37 8 .259 8 9 .568
CTþCC 96 107 .309 130 73 .280 75 128 .548 124 79 .657 124 79 .147 162 41 .143 25 37 .536
rs2289030
GG 118 119 156 81 81 156 146 91 154 83 178 59 23 39
CG 68 64 88 44 52 80 86 46 84 48 106 26 15 26
CC 8 11 .741 15 4 .505 4 15 .248 10 9 .532 13 6 .910 13 6 .366 2 3 .989
CGþCC 76 75 1.00 103 48 .707 56 95 .634 96 55 .777 97 54 .968 119 32 .474 17 29 1.000
rs2910164
CC 91 86 116 61 65 112 107 70 104 73 139 38 23 35
CG 77 82 104 55 59 100 106 53 111 48 121 38 14 23
GG 25 26 .854 39 12 .298 12 39 .175 28 23 .255 35 16 .087 36 15 .494 3 10 .531
CGþGG 102 108 .649 143 67 .671 71 139 .623 134 76 .566 146 64 .036 157 53 .453 17 33 .684
rs6505162
CC 117 127 170 74 80 164 151 93 157 87 183 61 28 37
AC 61 59 75 45 47 73 75 45 78 42 92 28 9 26
AA 14 7 .250 13 8 .344 8 13 .466 14 7 .909 14 7 .974 19 2 .276 2 5 .206
ACþAA 75 66 .376 88 53 .178 55 86 .262 89 52 .895 92 49 .946 111 30 .481 11 31 .117
rs7372209
CC 103 101 144 60 66 138 115 89 128 76 153 51 24 38
CT 73 81 96 58 57 97 106 48 105 49 120 34 13 26
TT 18 12 .441 19 11 .239 14 16 .263 21 9 .037 18 12 .485 24 6 .729 3 4 .816
CTþTT 91 93 .919 115 69 .114 71 113 .239 127 57 .014 123 61 .461 144 40 .524 16 30 .829
rs11614913
TT 57 42 64 35 35 64 66 33 63 36 80 19 11 17
CT 94 92 127 59 66 120 112 74 116 70 129 57 15 37
CC 42 59 .076 66 35 .788 36 65 .999 64 37 .555 72 29 .301 86 15 .005 14 12 .098
CTþCC 136 151 .103 193 94 .727 102 185 1.000 176 111 .408 188 99 .831 215 72 .292 29 49 1.000
miRNA, MicroRNA; postop, postoperative; M, male; F, female.
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APPENDIX TABLE 2. Multivariate analysis of clinicopathologic characteristics with the miRNA polymorphisms
P staging (n ¼ 388) Stage I Stage II/IIIA
rs2910164 I II/IIIA c2 P value HR (95% CI) c2 P value HR (95% CI) c2 P value
CC 104 73 1 1
CG 111 48 0.75 (0.32-1.76) .5141 0.39 (0.19-0.83) .0143
GG 35 16 .087 1.11 (0.38-3.22) .8512 0.30 (0.09-1.00) .0494
CGþGG 146 64 .036 0.84 (0.39-1.82) .6649 0.37 (0.19-0.72) .0033
Trend 0.98 (0.57-1.70) .9504 0.48 (0.28-0.80) .0054
Histology (n ¼ 388) Adeno Squamous
rs7372209 Adeno Squamous c2 P value HR (95% CI) c2 P value HR (95% CI) c2 P value
CC 115 89 1 1
CT 106 48 0.83 (0.39-1.77) .6238 1.55 (0.79-3.02) .1993
TT 21 9 .037 1.82 (0.59-5.57) .2970 0.93 (0.27-3.25) .9101
CTþTT 127 57 .014 0.95 (0.47-1.93) .8960 1.41 (0.74-2.67) .2940
Trend 1.13 (0.64-1.98) .6728 1.59 (0.73-1.85) .5395
Postop. complication (n ¼ 388) No Yes
rs11614913 No Yes c2 P value HR (95% CI) c2 P value HR (95% CI) c2 P value
TT 80 19 1 1
CT 129 57 0.57 (0.30-1.08) .0819 0.62 (0.20-1.93) .4065
CC 86 15 .005 0.61 (0.29-1.27) .1841 0.77 (0.17-3.45) .7325
CTþCC 215 72 .292 0.58 (0.33-1.04) .0664 0.65 (0.22-1.94) .4372
Trend 0.76 (0.51-1.11) .1559 0.84 (0.37-1.88) .6638
HR, Hazard ratio; CI, confidence interval.
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APPENDIX TABLE 3. The association between the 7 miRNA SNPs and RFS according to adjuvant chemotherapy
Adjuvant chemotherapy
No (n ¼ 303)
Adjuvant chemotherapy
Yes (n ¼ 85)
N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log–rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log–rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL
rs213210
AA 79 12 85 N.R. .382 Ref. 26 5 81 N.R. .691 Ref.
AG 143 26 82 N.R. 0.920 1.036 0.519 2.069 39 9 77 55.12 0.915 0.938 0.291 3.027
GG 80 16 80 N.R. 0.693 1.168 0.541 2.523 20 3 85 57.26 0.618 0.680 0.149 3.093
AGþGG 223 42 81 N.R. 0.816 1.080 0.563 2.072 59 12 80 55.12 0.790 0.858 0.279 2.640
Trend 0.686 1.083 0.735 1.596 0.630 0.836 0.403 1.733
rs895819
TT 135 25 81 93.76 .688 Ref. 50 7 86 N.R. .540 Ref.
CT 131 23 82 N.R. 0.372 0.763 0.422 1.381 27 9 67 55.12 0.031 3.299 1.113 9.779
CC 37 6 84 N.R. 0.436 0.693 0.276 1.740 8 1 88 57.26 0.800 0.750 0.082 6.907
CTþCC 168 29 83 N.R. 0.314 0.748 0.425 1.316 35 10 71 55.12 0.094 2.420 0.859 6.819
Trend 0.329 0.809 0.529 1.238 0.354 1.378 0.700 2.715
rs2289030
GG 184 31 83 N.R. .964 Ref. 53 10 81 57.26 .769 Ref.
CG 102 21 79 N.R. 0.845 1.058 0.598 1.873 30 7 77 N.R. 0.640 1.297 0.437 3.853
CC 17 2 88 N.R. 0.635 0.705 0.167 2.980 2 0 100 N.R. 0.993 NA
CGþCC 119 23 81 N.R. 0.965 1.013 0.581 1.764 32 7 8 N.R. 0.679 1.257 0.426 3.705
Trend 0.874 0.963 0.606 1.530 0.725 1.204 0.429 3.377
rs2910164
CC 139 31 78 N.R. .136 Ref. 38 12 68 52.92 .003 Ref.
CG 123 16 87 N.R. 0.178 0.657 0.356 1.211 36 4 89 55.12 0.030 0.228 0.060 0.864
GG 40 7 83 N.R. 0.448 0.724 0.315 1.666 11 1 91 N.R. 0.992 NA
CGþGG 163 23 86 N.R. 0.161 0.676 0.391 1.168 47 5 89 57.26 0.006 0.137 0.034 0.559
Trend 0.243 0.789 0.530 1.174 0.003 0.152 0.043 0.530
rs6505162
CC 194 33 83 N.R. .600 Ref. 50 11 78 N.R. .115 Ref.
AC 91 19 79 96.22 0.442 1.259 0.700 2.266 29 5 83 57.26 0.188 0.419 0.115 1.530
AA 15 2 87 N.R. 0.895 0.907 0.212 3.880 6 1 83 N.R. 0.284 0.309 0.036 2.644
ACþAA 106 21 80 N.R. 0.507 1.211 0.688 2.131 35 6 83 N.R. 0.130 0.391 0.116 1.319
Trend 0.639 1.118 0.703 1.777 0.147 0.493 0.189 1.284
rs7372209
CC 153 26 83 N.R. .582 Ref. 51 10 80 57.26 .494 Ref.
CT 121 21 83 N.R. 0.791 1.082 0.604 1.938 33 7 79 55.12 0.439 1.501 0.537 4.195
TT 29 7 76 N.R. 0.812 1.110 0.470 2.621 1 0 100 N.R. 0.993 NA
CTþTT 150 28 81 N.R. 0.758 1.089 0.634 1.870 34 7 79 55.12 0.463 1.471 0.525 4.122
Trend 0.763 1.062 0.720 1.565 0.529 1.373 0.512 3.681
(Continued)
G
en
era
l
T
h
o
ra
cic
S
u
rg
ery
Y
o
o
n
et
a
l
8
0
4
T
h
e
J
o
u
rn
a
l
o
f
T
h
o
ra
cic
a
n
d
C
a
rd
io
v
a
scu
la
r
S
u
rg
ery
c
O
cto
b
er
2
0
1
2
GTS
APPENDIX TABLE 3. Continued
Adjuvant chemotherapy
No (n ¼ 303)
Adjuvant chemotherapy
Yes (n ¼ 85)
N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log–rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log–rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL
rs11614913
TT 78 15 81 N.R. .527 Ref. 21 9 57 52.92 .037 Ref.
CT 144 26 82 N.R. 0.562 0.826 0.432 1.579 42 6 86 57.26 0.094 0.384 0.125 1.175
CC 80 13 84 N.R. 0.797 0.905 0.421 1.945 21 2 90 N.R. 0.043 0.181 0.035 0.944
CTþCC 224 39 83 N.R. 0.600 0.850 0.463 1.559 63 8 87 57.26 0.020 0.301 0.109 0.831
Trend 0.774 0.944 0.637 1.399 0.019 0.411 0.196 0.863
miRNA, MicroRNA; SNP, single nucleotide polymorphism; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; N.R., not reached.
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APPENDIX TABLE 4. The association between the 7 miRNA SNPs and RFS according to the pattern of nodal metastasis
Micrometastasis (n ¼ 40) Overt nodal metatstasis (n ¼ 68)
N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log-rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log–rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL
rs213210
AA 8 4 50 52.92 .774 Ref. 15 5 67 N.R. .784 Ref.
AG 20 7 65 N.R. 0.778 0.803 0.174 3.699 34 12 65 41.98 0.988 0.991 0.336 2.930
GG 12 4 67 42.38 0.551 1.768 0.272 11.494 19 5 74 N.R. 0.687 0.765 0.207 2.823
AGþGG 32 11 66 N.R. 0.963 0.966 0.230 4.067 53 17 68 N.R. 0.872 0.918 0.323 2.608
Trend 0.595 1.301 0.492 3.439 0.677 0.874 0.463 1.648
rs895819
TT 15 5 67 N.R. .710 Ref. 31 13 58 40.24 .083 Ref.
CT 17 8 53 42.38 0.247 2.355 0.552 10.040 28 7 75 N.R. 0.024 0.310 0.113 0.855
CC 8 2 75 N.R. 0.837 1.204 0.206 7.056 9 2 78 N.R. 0.108 0.280 0.059 1.320
CTþCC 25 10 60 42.38 0.343 1.829 0.525 6.369 37 9 76 N.R. 0.014 0.303 0.117 0.782
Trend 0.577 1.246 0.576 2.694 0.030 0.426 0.198 0.919
rs2289030
GG 23 8 65 52.92 .669 Ref. 39 13 67 57.26 .711 Ref.
CG 15 6 60 N.R. 0.431 0.592 0.161 2.180 26 8 69 N.R. 0.519 0.731 0.281 1.897
CC 2 1 50 N.R. 0.267 4.212 0.332 53.428 3 1 67 N.R. 0.885 0.856 0.104 7.046
CGþCC 17 7 59 N.R. 0.730 0.813 0.251 2.635 29 9 69 N.R. 0.529 0.742 0.293 1.877
Trend 0.974 1.017 0.370 2.798 0.593 0.802 0.356 1.803
rs2910164
CC 23 13 43 19.25 .015 Ref. 35 12 66 N.R. .426 Ref.
CG 14 2 86 N.R. 0.013 0.139 0.029 0.659 23 7 70 N.R. 0.581 0.766 0.297 1.976
GG 3 0 100 N.R. 0.994 NA 10 3 70 N.R. 0.452 0.609 0.167 2.219
CGþGG 17 2 88 N.R. 0.003 0.089 0.018 0.443 33 10 70 N.R. 0.431 0.711 0.304 1.660
Trend 0.004 0.117 0.027 0.495 0.402 0.776 0.429 1.404
rs6505162
CC 28 13 54 42.38 .139 Ref. 37 9 76 N.R. .177 Ref.
AC 9 2 78 N.R. 0.301 0.421 0.082 2.166 26 11 58 57.26 0.199 1.849 0.724 4.723
AA 2 0 100 N.R. 0.993 NA 5 2 60 38.63 0.554 1.625 0.325 8.116
ACþAA 11 2 82 N.R. 0.177 0.321 0.061 1.674 31 13 58 40.24 0.195 1.806 0.739 4.416
Trend 0.144 0.333 0.076 1.458 0.257 1.454 0.761 2.776
rs7372209
CC 24 8 67 N.R. .356 Ref. 38 12 68 N.R. .723 Ref.
CT 13 5 62 42.38 0.942 0.956 0.280 3.265 26 9 65 N.R. 0.982 1.011 0.402 2.540
TT 3 2 33 18.27 0.177 3.721 0.552 25.103 4 1 75 N.R. 0.321 0.351 0.044 2.782
CTþTT 16 7 56 42.38 0.732 1.216 0.397 3.725 30 10 67 N.R. 0.700 0.839 0.344 2.045
Trend 0.398 1.474 0.600 3.621 0.440 0.764 0.386 1.513
(Continued)
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APPENDIX TABLE 4. Continued
Micrometastasis (n ¼ 40) Overt nodal metatstasis (n ¼ 68)
N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log-rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL N
No.
relapsed
RFS
rate,%
Median
RFS (mo)
Log–rank
trend test,
P value
Prob
c2 HR
HR
lower CL
HR
upper CL
rs11614913
TT 11 6 45 36.09 .316 Ref. 17 7 59 38.63 .096 Ref.
CT 15 4 73 N.R. 0.184 0.349 0.074 1.651 37 14 62 57.26 0.549 0.743 0.281 1.964
CC 14 5 64 N.R. 0.032 0.166 0.032 0.859 12 1 92 N.R. 0.088 0.158 0.019 1.312
CTþCC 29 9 69 N.R. 0.050 0.238 0.057 1.002 49 15 69 N.R. 0.269 0.583 0.224 1.519
Trend 0.035 0.410 0.180 0.938 0.075 0.525 0.258 1.066
miRNA, MicroRNA; SNP, single nucleotide polymorphism; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; N.R., not reached.
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